Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Will supply raw materials for cell therapy production.
November 1, 2019
By: Tim Wright
Editor-in-Chief, Contract Pharma
Bio-Techne Corporation has unveiled plans to invest between $40-50 million to expand its GMP-grade protein production capacity. This investment will fund a new facility that is specifically dedicated to supporting the large-scale production of GMP-grade materials, including E. coli-derived recombinant proteins, which are an essential component for many bioprocessing and cell therapy manufacturing workflows. According to the company, the current global GMP-grade raw material supply for cell therapy production and industrial large molecule manufacturing is not sufficient to meet future demands. By investing in a new state-of-the-art GMP manufacturing facility, Bio-Techne is anticipating and preparing for the growing demand of such raw material to support the recent and forecasted surge in Investigational New Drug (IND) filings for autologous and allogeneic cell therapies. This corporate infrastructure investment complements the 30-year history of Bio-Techne’s R&D Systems brand as an industry leader in recombinant protein manufacturing. “As the promising science behind emerging cell and gene therapy applications continues to demonstrate therapeutic effectiveness, the focus must now be on supply and scale,” said Dave Eansor, president of Bio-Techne’s protein sciences segment. “By investing in a new GMP facility, therapeutic manufacturers can be assured that the highly pure, bioactive R&D Systems GMP-grade proteins they rely on for their manufacturing process will continue to be available as their raw material demands increase through clinical trial, approval, and therapeutic commercialization.” Chuck Kummeth, president and chief executive officer, Bio-Techne, said, “The recent success of cell and gene therapies is very exciting. This investment solidifies our commitment to supporting the future of these new modalities by finding innovative and reliable ways to help companies gain access to scalable quantities and a reliable supply of high-quality, GMP-grade growth factors and cytokines for their manufacturing processes.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !